The new development programs include response prediction to ovarian cancer treatment, predicting risk of gastric cancer recurrence, and differentiation of small cell from non-small cell lung cancer. The company expects to develop and market the new tests through its own clinical laboratory improvement amendments CLIA-certified laboratory, for which the company recently signed a binding acquisition term sheet.
Leveraging unique microRNA biomarkers identified using Rosetta Genomics’s proprietary microRNA extraction and quantification methods, the new programs are expected to be clinically available during 2009-2010.
Ronen Tamir, executive vice president of marketing and communication at Rosetta, said: “Our rich product pipeline, combined with the upcoming acquisition of a commercial CLIA-certified laboratory, will position us to participate in such a growth trend in the molecular diagnostics industry.”